Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Hummingbird Ventures

Founders Barend Van den Brande

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 118
Average round size
info
The average size of a deal this fund participated in
$18M
Portfolio companies 67
Rounds per year 4.92
Lead investments 12
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.40
Exits 9
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Financial Services
  • E-Commerce
  • Software
  • Health Care
  • Internet
Summary

In 2000 was created Hummingbird Ventures, which is appeared as VC. The company was established in Europe in Belgium. The leading representative office of defined VC is situated in the Gent.

We also calculated 2 valuable employees in our database.

Among the most popular portfolio startups of the fund, we may highlight Kraken Bitcoin Exchange, Deliveroo, Showpad. Among the most popular fund investment industries, there are Health Care, Financial Services. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United Kingdom. The fund has no exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Hummingbird Ventures, startups are often financed by Y Combinator, Index Ventures, Swisscom Ventures. The meaningful sponsors for the fund in investment in the same round are Y Combinator, Nevzat Aydin, Kaan Karamanci. In the next rounds fund is usually obtained by VentureSouq, Insight Partners, Index Ventures.

The increased amount of exits for fund were in 2017. Opposing the other organizations, this Hummingbird Ventures works on 16 percentage points less the average amount of lead investments. The fund is generally included in 2-6 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top activity for fund was in 2019. Speaking about the real fund results, this VC is 1 percentage points less often commits exit comparing to other organizations.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Hummingbird Ventures:
Typical Co-investors
Hummingbird Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Hummingbird Ventures:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Backcast Partners New York, New York, United States
BuenTrip Ventures Ecuador, Pichincha, Quito
E.ON Venture Partners Düsseldorf, Germany, Nordrhein-Westfalen
Exor Croatia, Grad Zagreb, Zagreb
Fortino Capital Belgium, Vlaams-Brabant, Zaventem
Gladium Gothenburg, Sweden, Vastra Gotaland
iFund Japan, Tokyo
KDG Beijing, Beijing, China
LD Capital China, Shanghai, Shanghai
Lufthansa Cargo Frankfurt, Germany, Hessen
MAGIX Nevada, Reno, United States
Net Fund Europe -
Nihonshokken Ehime Prefecture, Imabari, Japan
Pearson England, London, United Kingdom
Rosseau Asset Management Canada, Ontario, Toronto
Spinventure Angleur, Belgium, Liege
Taihuoniao Beijing, Beijing, China
Technology 9 Labs (T9L) Delhi, India, New Delhi
Teligence Capital British Columbia, Canada, Vancouver
WaterBridge Ventures Delhi, India, New Delhi

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Leya

$10M16 May 2024 Stockholm, Södermanland, Sweden

Anima

Health Care
Medical
mHealth
Mobile Apps
$12M19 Mar 2024 London, England, United Kingdom

Bioptimus

$35M20 Feb 2024 Paris, Ile-de-France, France

Monumental

Construction
Robotics
Software
$27M15 Feb 2024 Amsterdam, Noord-Holland, The Netherlands

Bright Money

Artificial Intelligence
Credit Cards
Finance
Financial Services
FinTech
Personal Finance
$12M27 Sep 2023 San Francisco, California, United States

BioLoomics

Biotechnology
Health Care
Sensor
$8M19 Sep 2023 Boulder, Colorado, United States

Hubflo

CRM
Enterprise Resource Planning (ERP)
Project Management
SaaS
Software
$2M08 Sep 2023 Paris, Ile-de-France, France

Noetik

Biotechnology
Life Science
$14M07 Sep 2023 South San Francisco, California, United States

Amber Bio

Biotechnology
Pharmaceutical
$26M03 Aug 2023 -
News
BillionToOne Closes $55M Series B Funding

– BillionToOne, Inc. from Menlo Park develops molecular diagnostics company.
– The company closed a $55m Series B funding round.
– The round was led by existing investor Hummingbird Ventures and incoming investor Four Rivers Group with participation from Neotribe Ventures, Norwest Venture Partners, Y Combinator, and Libertus Capital.
– The new investment will be used to expand the company’s clinical lab and commercial team nationwide.

Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital

– Enveda Biosciences announced an oversubscribed $51M Series A funding round.
– The financing was led by Lux Capital with participation from Two Sigma Ventures, Hummingbird VC, Catalio Capital, Lifeforce Capital, and Matthew De Silva of Notable Labs along with existing investors True Ventures, Wireframe Ventures, Village Global, and Chris Gibson of Recursion.
– Nature is the greatest source of therapeutics we know, yet 95 percent of the natural world is a chemical mystery. Enveda is systematically exploring this unknown space to unlock its potential for new medicines with the first high-resolution chemical map of the natural world.
– This new investment will further power Enveda’s data-driven approach to screening, validating, and developing high-potential natural compounds into first-in-class clinical candidates.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Hummingbird Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 118
Average round size 18M
Rounds per year 4.92
Peak activity year 2022
Lead investments 12
Follow on index 0.40
Exits 9
Group Appearance index 0.82

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Leya

$10M16 May 2024 Stockholm, Södermanland, Sweden

Anima

Health Care
Medical
mHealth
Mobile Apps
$12M19 Mar 2024 London, England, United Kingdom

Bioptimus

$35M20 Feb 2024 Paris, Ile-de-France, France

Monumental

Construction
Robotics
Software
$27M15 Feb 2024 Amsterdam, Noord-Holland, The Netherlands

Bright Money

Artificial Intelligence
Credit Cards
Finance
Financial Services
FinTech
Personal Finance
$12M27 Sep 2023 San Francisco, California, United States

BioLoomics

Biotechnology
Health Care
Sensor
$8M19 Sep 2023 Boulder, Colorado, United States

Hubflo

CRM
Enterprise Resource Planning (ERP)
Project Management
SaaS
Software
$2M08 Sep 2023 Paris, Ile-de-France, France

Noetik

Biotechnology
Life Science
$14M07 Sep 2023 South San Francisco, California, United States

Amber Bio

Biotechnology
Pharmaceutical
$26M03 Aug 2023 -
Crunchbase icon

Content report

The following text will be sent to our editors: